You are here » Home » Companies » Company Overview »


BSE: N.A. Sector: N.A.
NSE: N.A. ISIN Code: N.A.
BSE 05:30 | 01 Jan
NSE 05:30 | 01 Jan

. () - Chairman Speech

Company chairman speech

DOCTORS BIOTECH INDIA LIMITED ANNUAL REPORT 2002-2003 CHAIRMAN'S REPORT CHAIRMAN'S SPEECH Dear Members, The progress of mankind in recent years has been inextricably linked with the growth and advancement in the biotechnology sector, which chiefly consist of biotechnology products as its key components. I am delisted to the communicating with you at a time when the Indian economy is in great tempo and is full of a rich small of recovery. The economic fundamentals are robust and we are poised for achieving sound and durable growth. India's economy stands out in a recession marred world. The Company realize the characteristics of the past 2005 era and therefore, has been active on both ends, creating long term value through research in the field of biotechnology as well as in-house R & D Capabilities. The Company has set higher objectives as well as high standards for itself to create its biotechnology base, which will incash the opportunities in the untapped biotech field. The Company's vision is to create high values through biotechnology, globally and hence it has undertaken a mission to develop brand equity. We have had a bountiful monsoon this year. The corporate results announced so far are profit laden and the business confidence levels are at an all time high in recent years. Expansion and diversification is being planned what has also helped is that the international perception about India is changing. The world now views India as a locomotive economy, which has the potential to drive global growth. Indian entrepreneurs too are changing their outlook and are making moves compatible with international horizons. Your Company's performance during the year under review, has also encouraged us to review and recalibrate our business strategy. We have identified biotechnology as gold mines, where we foresee a superb potential for the Company. The changed name indicate our new vision and corporate resolve. Based on expert advice, views and suggestions, we have embarked on a foray into the manufacture of RDNA products, which have a ready untapped market. The projects has been favourably appraised and is poised to be off the drawing board very soon. Keeping in view a buoyant capital market, we have firmed up appropriate plans for funding the planned biotechnology project. India has the potential to repeat its IT success story in the biotech sector and we are confident of boarding this bus, at the right moment. We are confident of the Company's capability to embark upon such ventures, and hope to reap rich rewards there from, for our shareholders and other stakeholders. Sincerely Yours, (Vijay M Jain) Chairman